MedTrace Logo

Effect of High Intensity Interval Training in Patients With Multiple Sclerosis

NCT05954195 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2023-07-20

No results posted yet for this study

Summary

In this study, we are aiming to systematically review the literature on the effect of HIIT on MS patients as improving physical performance, cognitive function, aerobic fitness and muscle strength. This could help guide the development of standardized clinical guidelines and direct clinical decision making by the physical therapists whether to implement this type of exercises or not.

Conditions

Interventions

OTHER

high intensity interval training

high intensity interval training through ergometer, with whole treatment session between 20 - 30 minutes divided into 3 parts, the 1st is warming up (40% of HRmax intensity for 2/3/5 minutes then the active training part (intervals of 85-90% of HRmax for 1 minute then rest period of 1 minute of 40 % of HRmax and so on for nearly 20 minutes ) then the last part is cooling down (30 % of HRmax for 3/5 minutes).

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Abeer Abobakr Dr Alwishy, Professor · Physical therapy for neuromuscular disorders and its surgeries, Cairo university

  • Neveen Mohy-Eldin shalaby, professor · Faculty of medicine, Alqasr elainy, Cairo university

  • Hossam M. Elsaid, lecturer · Faculty of physical therapy of neuromuscloskeletal disorders and its surgeries, Cairo universities

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-20
Primary Completion
2023-11-30
Completion
2023-12-18

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05954195 on ClinicalTrials.gov